<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41982">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02065024</url>
  </required_header>
  <id_info>
    <org_study_id>AGL2012-39503-C02-02</org_study_id>
    <nct_id>NCT02065024</nct_id>
  </id_info>
  <brief_title>Food Matrix and Genetic Variability as Determinants of Bioavailability and Biological Effects of Beta-cryptoxanthin and Phytosterols</brief_title>
  <acronym>foodmagenpol</acronym>
  <official_title>Food Matrix and Genetic Variability as Determinants of the Bioavailability and Biological Effects of a B-cryptoxanthin and Phytosterols-enriched Beverage; In Vitro and in Vivo Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Puerta de Hierro University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Puerta de Hierro University Hospital</source>
  <oversight_info>
    <authority>Spain: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Regular consumption of a beverage containing Î²-cryptoxanthin (b-Cx) and plant sterols (Ps)
      has been shown to exert a synergic effect in reducing cardiovascular risk and bone
      remodeling markers (formation and resorption). The present project aims to assess the
      influence of technological treatment and genetic variability on the bioavailability and the
      health effects of the added components (Ps, b-Cx), in particular to their potential role in
      prevalent disorders.In vitro and in vivo studies will be carried out to this effect. In
      vitro and in vivo studies (human intervention study) will be performed and cardiovascular,
      bone turnover and inflammation markers will be evaluated. Additionally, an in vitro colonic
      fermentation model and cell cultures will be used to  explore anticarcinogenic effects and
      potential cytotoxicity.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>serum response of B-cryptoxanthin</measure>
    <time_frame>6 weeks of intervention</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum response of phytosterols</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum lipid profile</measure>
    <time_frame>6 weks of intervention</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone resorption markers</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>interleukins</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum C-reactive protein</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone formation markers</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Intestinal transporters polymorphisms,</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>b-cryptoxanthin plus phytosterols</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fruit and milk based beverage enriched with b-cryptoxanthin and phytosterols</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fruit and milk based beverage not enriched</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>b-cryptoxanthin plus phytosterols</intervention_name>
    <arm_group_label>b-cryptoxanthin plus phytosterols</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post-menopausal women; mild hypercholesterolemia

        Exclusion Criteria:

          -  Use of cholesterol lowering drugs, hormonal therapy, vitamin and herbs supplements
             use
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro-Majadahonda</name>
      <address>
        <city>Majadahonda (Madrid)</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>March 3, 2014</lastchanged_date>
  <firstreceived_date>February 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Puerta de Hierro University Hospital</investigator_affiliation>
    <investigator_full_name>Fernando Granado Lorencio</investigator_full_name>
    <investigator_title>dr Fernando Granado Lorencio</investigator_title>
  </responsible_party>
  <keyword>b-cryptoxanthin</keyword>
  <keyword>plant sterols</keyword>
  <keyword>serum Cholesterol</keyword>
  <keyword>bone turnover markers</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cryptoxanthin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
